OV101

Phase 3Small molecule

HHealx AI

OV101 is one of 45 small molecule programs targeting Fragile X Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fragile X SyndromeActive, not recruiting

Angelman SyndromeActive, not recruiting

Fragile X SyndromePhase 2

Active, not recruiting

Angelman SyndromePhase 3

Active, not recruiting

Competition

Competitive Landscape

46 competitors in Fragile X Syndrome

#DrugCompanyPhaseTrials

Epidiolex

Glucophage

4 3

Daliresp

Namenda

Lioresal

Rilutek

AAzurity Pharmaceuticals

Approved

1 7

Altoprev

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

1 8

Minocin

TTriax

Approved

1 9

Lithobid

SSolvay Pharmaceuticals

Approved

—10

Clinoril

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Angelman syndrome2 trials

A Study in Adults and Adolescents With Angelman Syndrome (STARS)

Completed·HHealx AI·Phase 2·NCT02996305·88 enrolled

An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome

Terminated·HHealx AI·Phase 3·NCT03882918·141 enrolled

Single Dose1 trial

Single Dose Pharmacokinetic (PK) Study

Completed·HHealx AI·Phase 1·NCT03109756·12 enrolled

Fragile X Syndrome1 trial

A Study of OV101 in Individuals With Fragile X Syndrome

Completed·HHealx AI·Phase 2·NCT03697161·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for OV101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OV101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OV101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Healx AI company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHealx AI

OV101

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Angelman syndrome2 trials

Single Dose1 trial

Fragile X Syndrome1 trial

References

Drug Info

Quick Facts

Related News